Tarsus Pharmaceuticals, Inc.
TARSBiological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001819790
Revenue FY2025
$451.0M
Net Income
$(66.0M)
EPS (Basic)
$-1.59
Net Margin
-14.7%
ROE
-19.3%
Total Equity
$343.0M
Shares Out
44M
Tarsus Pharmaceuticals, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 2 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
OrbiMed Advisors
OrbiMed Advisors
$2.2M
0.0%
NEW
Alps Advisors
Alps Advisors
$2.7M
0.0%
+25.2%
Insider Transactions
Reading stored insider transactions…